Form 4: Beam Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
John M. Evans, CEO and a Director of Beam Therapeutics Inc., sold 50,000 shares of common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 25,000 Common Stock at $1.03 ($25,750) on October 15, 2026; holds 1,072,205 after (Direct).
- Open-market sale: disposed of 25,000 Common Stock at $23.57 ($589,150) on October 15, 2026; holds 1,047,205 after (Direct).
- Option exercise/conversion: acquired 25,000 Common Stock at $1.03 ($25,750) on October 16, 2026; holds 1,072,205 after (Direct).
- Open-market sale: disposed of 25,000 Common Stock at $23.98 ($599,595) on October 16, 2026; holds 1,047,205 after (Direct).
- Option exercise/conversion: disposed of 25,000 Stock Option (Right to Buy) on October 15, 2026; holds 180,804 after (Direct).
- Option exercise/conversion: disposed of 25,000 Stock Option (Right to Buy) on October 16, 2026; holds 155,804 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,188,745 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
John M. Evans — Director, Officer (CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 25,000 | $1 | $25.8K | 1,072,205 |
| 2026-10-15 | Open-market sale | Common Stock | 25,000 | $24 | $589.1K | 1,047,205 |
| 2026-10-16 | Option exercise/conversion | Common Stock | 25,000 | $1 | $25.8K | 1,072,205 |
| 2026-10-16 | Open-market sale | Common Stock | 25,000 | $24 | $599.6K | 1,047,205 |
| 2026-10-15 | Option exercise/conversion | Stock Option (Right to Buy) | 25,000 | — | — | 180,804 |
| 2026-10-16 | Option exercise/conversion | Stock Option (Right to Buy) | 25,000 | — | — | 155,804 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (25,000 shares) |
| 2026-10-15 | Open-market sale (25,000 shares) |
| 2026-10-16 | Option exercise/conversion (25,000 shares) |
| 2026-10-16 | Open-market sale (25,000 shares) |
| 2026-10-15 | Option exercise/conversion (25,000 shares) |
| 2026-10-16 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, BEAM, Beam Therapeutics Inc., bearish, John M. Evans
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.